Speciality Medicines Ltd (544738) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 544738 | NSE: | Trading |

Speciality Medicines Share Price

125.90 1.90 0.00%
as on 30-Mar'26 16:59

DeciZen - make an informed investing decision on Speciality Medicines

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Speciality Medicines stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
12.85
Market Cap:
110.6 Cr.
52-wk low:
124
52-wk high:
129.5

Is Speciality Medicines Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Speciality Medicines: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Speciality Medicines Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 69.8%52.4%37.7%34.5%-
Value Creation
Index
4.02.71.71.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 40.423.227.558.358
Sales YoY Gr.--42.5%18.4%111.7%-
Adj EPS 4.74.45.613.29.8
YoY Gr.--6%25.6%136.9%-
BVPS (₹) 6.115.429.447.337.3
Adj Net
Profit
1.51.72.88.59
Cash Flow from Ops. 0.8-4.2-4.8-5.8-
Debt/CF from Ops. 1.5-0.9-0.6-0.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA13%111.7%
Adj EPS NANA40.9%136.9%
BVPSNANA97.6%60.5%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
76.643.327.137.223.2
Op. Profit
Mgn %
5.615.419.215.7NAN
Net Profit
Mgn %
3.77.310.314.514.8
Debt to
Equity
0.60.60.20.2-
Working Cap
Days
01152111810
Cash Conv.
Cycle
0801601320

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Speciality Medicines Ltd.

Standalone Consolidated
TTM EPS (₹) 9.8 1.9
TTM Sales (₹ Cr.) 58.3 23.2
BVPS (₹.) 37.3 10
Reserves (₹ Cr.) 24 -
P/BV 3.38 12.59
PE 12.85 65.22
From the Market
52 Week Low / High (₹) 124.00 / 129.50
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 111
Equity (₹ Cr.) 8.8
Face Value (₹) 10
Industry PE 20.9

Management X-Ray of Speciality Medicines:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Speciality Medicines - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Speciality Medicines

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales40232858
Operating Expenses 38202249
Manufacturing Costs0000
Material Costs35161842
Employee Cost 1111
Other Costs 2236
Operating Profit 2459
Operating Profit Margin (%) 5.6%15.4%19.2%15.7%
Other Income 0000
Interest 0011
Depreciation 0000
Exceptional Items 0000
Profit Before Tax 2359
Tax 1120
Profit After Tax 1239
PAT Margin (%) 3.7%7.3%10.7%14.8%
Adjusted EPS (₹)4.74.45.713.4
Dividend Payout Ratio (%)0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 261530
Share Capital 0456
Reserves 221024
Minority Interest0000
Debt1334
Long Term Debt0113
Short Term Debt1221
Trade Payables1221
Others Liabilities 1335
Total Liabilities 6132340

Fixed Assets

Gross Block2223
Accumulated Depreciation0011
Net Fixed Assets 2212
CWIP 0000
Investments 0000
Inventories05817
Trade Receivables361110
Cash Equivalents 0001
Others Assets 01210
Total Assets 6132340

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1-4-5-6
PBT 2359
Adjustment 0111
Changes in Working Capital -1-7-9-15
Tax Paid 0-1-10
Cash Flow From Investing Activity -20-0-2
Capex -2-0-0-1
Net Investments -000-0
Others -0-00-1
Cash Flow From Financing Activity 2458
Net Proceeds from Shares 0267
Net Proceeds from Borrowing 01-12
Interest Paid -0-0-1-0
Dividend Paid 0000
Others 110-0
Net Cash Flow 00-01

Finance Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)76.5643.328.0337.85
ROCE (%)69.7552.4137.7234.47
Asset Turnover Ratio72.441.531.86
PAT to CFO Conversion(x)1-2-1.67-0.67
Working Capital Days
Receivable Days236410864
Inventory Days4408480
Payable Days12334215

Speciality Medicines Ltd Stock News

Speciality Medicines Ltd FAQs

The current trading price of Speciality Medicines on 30-Mar-2026 16:59 is ₹125.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Mar-2026 the market cap of Speciality Medicines stood at ₹110.6.
The latest P/E ratio of Speciality Medicines as of 29-Mar-2026 is 12.85.
The latest P/B ratio of Speciality Medicines as of 29-Mar-2026 is 3.38.
The 52-week high of Speciality Medicines is ₹129.5 and the 52-week low is ₹124.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Speciality Medicines is ₹58.27 ( Cr.) .

About Speciality Medicines Ltd

Speciality Medicines was originally incorporated as ‘Speciality Medicines Private Limited’ as a Private Limited Company on February 05, 2021. Later on, pursuant to a special resolution passed by its shareholders in the extra-ordinary general meeting held on April 04, 2024, the company was converted from a private limited company to public limited company and consequently, the name of the company was changed from ‘Speciality Medicines Private Limited’ to ‘Speciality Medicines Limited’ on June 25, 2024.

It is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. It offers a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Its products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. It operates through two integrated business models: (a) Manufacturing, through contract manufacturing basis, of approved finished formulations and distribution internationally and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers.

Under its contract manufacturing arrangement, its contract manufacturer based in India is responsible for the manufacturing of speciality pharmaceutical formulations. These formulations are either approved or currently undergoing the approval process with the relevant health authorities in the target countries. Once the necessary regulatory approvals are obtained, it initiates its role as the distributor for these products. Its responsibilities include overseeing the marketing and distribution of the approved specialty pharmaceutical products across multiple international markets. Under its other business model, it operates as a distributor of specialty pharmaceutical products sourced from manufacturers. Its role focuses on the procurement, warehousing, and wholesale distribution of these medicines to a wide network of healthcare providers and retailers. It ensures smooth supply chain operations and timely delivery across various regions. Its services are centred on maintaining consistent product availability and supporting its customers through reliable and efficient distribution.

Business area of the company

The company is primarily engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its products are supplied to both domestic and international markets.

Products categories of the company

  • Anti-Cancer: Medicines for prevention, control, or treatment of different types of cancers including solid tumours and blood cancers. 
  • Vaccines (Human & Veterinary): Preventive 155mmunization products to protect humans and animals from viral and bacterial diseases. 
  • Critical Care: High-urgency medicines used in intensive care units for life-saving interventions and severe medical conditions. 
  • Anti-Diabetic: Therapies to manage blood glucose levels in patients with Type 1 and Type 2 diabetes.
  • Gynecology: Medicines for women’s reproductive health, hormonal balance, and pregnancy-related conditions. 
  • Nephrology: Treatments for chronic kidney diseases, dialysis support, and electrolyte management.
  • Dermatology: Medications for skin infections, inflammatory skin disorders, and dermatological maintenance.
  • Anti-Hypertensive: Drugs to control high blood pressure and prevent related cardiovascular complications.
  • Anti-Malarial: Medicines for the prevention and treatment of malaria caused by Plasmodium parasites.
  • Antibiotics (Human & Veterinary): Broad- and narrow-spectrum drugs to treat bacterial infections in humans and animals.
  • Antiviral Therapies: Targeted treatments for viral infections such as Hepatitis B, Hepatitis C, HIV, COVID19, and Influenza.
  • Chronic & Autoimmune Disorders: Long-term disease management including thyroid disorders, arthritis, and autoimmune-related inflammation. 
  • Ophthalmic Care: Treatments for eye conditions such as glaucoma, infections, and vision-related issues.
  • Anti-TB: Multi-drug regimens for the treatment and eradication of tuberculosis. 
  • Steroid Therapy: Anti-inflammatory and immunosuppressive medicines used in acute and chronic conditions.
  • Anti-Fungal: Drugs to prevent or treat fungal infections affecting skin, nails, and internal organs.
  • Ayurvedic & Herbal: Herbal formulations and alternative medicines for wellness and therapeutic support.
  • Erectile Dysfunction: Medicines to improve male sexual function and address erectile disorders.
  • Dental Products: Products for oral hygiene, dental infection control, and gum disease management.
  • Vitamins & Supplements: Nutritional support products, including vitamin and mineral supplements, for overall health maintenance.
  • Surgical Products: Supplies and consumables used in surgical procedures and hospital care.
  • Symptom Relief: Medicines to reduce fever, pain, and other common discomforts.

History and milestones

  • 2021: Incorporation of the company viz. ‘Speciality Medicines Private Limited’.
  • 2021: The company shifted its operation to Mumbai, Maharashtra, India 
  • 2022: The company was recognized as Start-up by Department for Promotion of Industry and Internal Trade 
  • 2023: The company received certificate as an eligible business by Inter-Ministerial Board to avail Income Tax benefits under Section 80-IAC of the Income Tax Act, 1961.
  • 2024: Conversion of the company from private limited to public limited company.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×